Bicara Therapeutics Inc.
BCAXHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bicara Therapeutics Inc. focuses on Biotechnology services and products. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. The $1.43B market capitalization puts BCAX squarely in small-cap range for its industry. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Market Cap
$1.43B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.99
EPS (TTM)
$-2.77
EPS (Fwd)
$-3.63
ROE
-32.3%
ROA
-21.1%
Cash
$539.8M
Total Debt
$1.4M
Free CF
-$68.4M
52W Change
119.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $539.8M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$68.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -32.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BCAX.